Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

2.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
3.

Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.

Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD.

J Urol. 2009 Jun;181(6):2608-15. doi: 10.1016/j.juro.2009.01.117. Epub 2009 Apr 16.

4.

Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis.

Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, Chen H.

Urol Int. 2013;91(4):429-38. doi: 10.1159/000351037. Epub 2013 Aug 16. Review.

PMID:
23970316
5.

Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M.

Eur Urol. 2012 Sep;62(3):507-14. doi: 10.1016/j.eururo.2011.12.056. Epub 2012 Jan 5.

PMID:
22236796
6.

Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.

Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC.

J Urol. 2014 Dec;192(6):1743-9. doi: 10.1016/j.juro.2014.07.008. Epub 2014 Jul 18.

PMID:
25046622
7.

Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.

Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F; VESITOX study group in France.

Eur Urol. 2012 Mar;61(3):520-9. doi: 10.1016/j.eururo.2011.10.028. Epub 2011 Oct 25.

PMID:
22036776
8.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Review.

PMID:
22161392
9.

Refractory idiopathic urge urinary incontinence and botulinum A injection.

Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network.

J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028. Epub 2008 May 21.

10.

Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.

Lahdes-Vasama TT, Anttila A, Wahl E, Taskinen S.

Scand J Urol Nephrol. 2011 Dec;45(6):397-400. doi: 10.3109/00365599.2011.590997. Epub 2011 Jul 8.

PMID:
21740110
11.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.

PMID:
23246476
12.

Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.

Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Wei J, Chai T, Janz N, Spino C, Meikle S; Pelvic Floor Disorders Network.

Contemp Clin Trials. 2012 Jan;33(1):184-96. doi: 10.1016/j.cct.2011.09.019. Epub 2011 Oct 8.

13.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie J, Wilson DI, Herbison GP, Wilson D.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493. Review. Update in: Cochrane Database Syst Rev. 2011;(12):CD005493.

PMID:
17636801
14.

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.

J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016/j.juro.2012.01.125. Epub 2012 Apr 12.

PMID:
22503020
15.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
16.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.

BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.

18.
19.

Botulinum toxin as a treatment for refractory overactive bladder.

Harris S, Rizzolo D.

JAAPA. 2016 Feb;29(2):1-4. doi: 10.1097/01.JAA.0000476217.57808.c4. Review.

PMID:
26818640
20.

Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF; Pelvic Floor Disorders Network.

N Engl J Med. 2012 Nov 8;367(19):1803-13. doi: 10.1056/NEJMoa1208872. Epub 2012 Oct 4.

Supplemental Content

Support Center